Underlying data for ‘Association of leukocyte nadir with complete remission in Indonesian acute myeloid leukemia patients undergoing 7+3 remission induction chemotherapy’

This is a dataset of prognostic study with a retrospective cohort design. The sample was taken by total sampling from the medical record data of patients with a diagnosis of AML who were not acute promyelocytic leukemia (APL) or AML M3 FAB classification who underwent 7+3 induction chemotherapy at Dharmais Hospital National Cancer Center and Dr. Cipto Mangunkusumo National Central Public Hospital during the period from January 1st, 2015 to December 31st, 2019. The study was approved by the Universitas Indonesia Ethics Board, approval number KET-603/UN2.F1/ETIK/PPM.00.02/2021. Data was collected from June 15th to August 31st 2021.
The acceptance criteria of this study were patients aged ≥18 years, diagnosed of AML based on at least bone marrow smear or biopsy and bone marrow aspirate or peripheral blood immunophenotyping, underwent first-line remission induction chemotherapy 7+3 regimen, and had never undergone any remission induction chemotherapy before. The criteria for rejection were AML M3 (FAB criteria) or acute promyelocytic leukemia (APL), a myeloblastic crisis phase of chronic myeloid leukemia (CML) or when the required data was not found in the patient's medical record.
The nadir leukocyte level and the time required to reach it were assessed for their associations to the occurrence of CR during the evaluation of 7+3 remission induction chemotherapy treatment. Treatment evaluations were done when the peripheral blood cells had recovered. The criteria used to define the occurrence of CR during treatment evaluation were in accordance with those established by European LeukemiaNet 2017. Factors considered as potential confounders were age, gender, AML subtype, Charlson Comorbidity Index (CCI), history of myelodysplasia syndrome (MDS), history of chemotherapy/radiotherapy, prechemotherapy leukocyte level, bone marrow myeloblast cell level at diagnosis, occurrence of febrile neutropenia and administration of granulocyte colony stimulating factor (GCSF).